[{"id":"26646272-f3f1-4cb9-84dd-16ded62b0796","acronym":"","url":"https://clinicaltrials.gov/study/NCT01875601","created_at":"2021-01-29T07:04:49.340Z","updated_at":"2025-02-25T12:36:34.409Z","phase":"Phase 1","brief_title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT01875601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2025-02-24"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"fc2b490f-716a-4fb8-8ba2-7e656cf95939","acronym":"SURPASS","url":"https://clinicaltrials.gov/study/NCT04044859","created_at":"2021-01-18T19:50:41.997Z","updated_at":"2024-07-02T16:35:19.014Z","phase":"Phase 1","brief_title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","source_id_and_acronym":"NCT04044859 - SURPASS","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 04/30/2037","study_completion_date":" 04/30/2037","last_update_posted":"2024-02-16"},{"id":"5946fd69-e35c-4966-a99b-d42d265fb810","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505813","created_at":"2021-03-12T18:53:10.090Z","updated_at":"2024-07-02T16:35:23.473Z","phase":"Phase 1/2","brief_title":"Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma","source_id_and_acronym":"NCT04505813","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A","pipe":"","alterations":" ","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NEXI-002"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-15"},{"id":"5fc95c78-0abd-4ca1-9e8e-6011739ca3e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284228","created_at":"2021-01-18T20:47:52.551Z","updated_at":"2024-07-02T16:35:23.484Z","phase":"Phase 1/2","brief_title":"Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT","source_id_and_acronym":"NCT04284228","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-15"},{"id":"6f412c81-9eb0-48e7-8b40-e0e8b91d12d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05582590","created_at":"2022-10-17T13:56:01.481Z","updated_at":"2024-07-02T16:35:23.356Z","phase":"Phase 1","brief_title":"Autologous T Cells Targeting HPV16 HPV18 \u0026 Survivin in Patients With R/R HPV-related Oropharyngeal Cancers","source_id_and_acronym":"NCT05582590","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A","pipe":"","alterations":" ","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-003"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 08/25/2027","study_completion_date":" 08/25/2027","last_update_posted":"2024-01-15"},{"id":"d4c2f1f7-7ab0-4565-bc0b-f59cf09aba7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01572493","created_at":"2023-03-06T20:01:22.302Z","updated_at":"2024-07-02T16:35:54.091Z","phase":"Phase 1","brief_title":"Continuous Infusion of rhIL-15 for Adults With Advanced Cancer","source_id_and_acronym":"NCT01572493","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • TNFA • IL15","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/04/2012","start_date":" 04/04/2012","primary_txt":" Primary completion: 06/20/2019","primary_completion_date":" 06/20/2019","study_txt":" Completion: 07/02/2019","study_completion_date":" 07/02/2019","last_update_posted":"2023-03-06"},{"id":"71343729-1bac-4081-80f8-a294b7151b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04185220","created_at":"2021-01-18T20:24:07.273Z","updated_at":"2024-07-02T16:35:58.235Z","phase":"Phase 1","brief_title":"Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome","source_id_and_acronym":"NCT04185220","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • IL15","pipe":"","alterations":" ","tags":["TNFRSF8 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 05/18/2022","study_completion_date":" 05/18/2022","last_update_posted":"2023-01-04"},{"id":"e4dfc3e3-609f-407a-81af-e186b7ede706","acronym":"","url":"https://clinicaltrials.gov/study/NCT03905135","created_at":"2021-01-18T19:13:31.837Z","updated_at":"2024-07-02T16:36:04.092Z","phase":"Phase 1","brief_title":"Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies","source_id_and_acronym":"NCT03905135","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • IL15 • IL5","pipe":" | ","alterations":" PD-L1 expression","tags":["TNFRSF8 • IL15 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-09-13"},{"id":"a007902a-0a7f-41d6-85c9-d3d6c51f4f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689453","created_at":"2021-01-18T13:07:06.175Z","updated_at":"2024-07-02T16:36:11.245Z","phase":"Phase 1","brief_title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","source_id_and_acronym":"NCT02689453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-04-29"},{"id":"ec2197c4-0016-4dba-b7ff-d215f60c5c5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01727076","created_at":"2021-01-18T07:32:38.065Z","updated_at":"2024-07-02T16:37:17.894Z","phase":"Phase 1","brief_title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","source_id_and_acronym":"NCT01727076","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTLA4 • LAMP1 • IL15","pipe":"","alterations":" ","tags":["CTLA4 • LAMP1 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/15/2013","start_date":" 02/15/2013","primary_txt":" Primary completion: 06/30/2016","primary_completion_date":" 06/30/2016","study_txt":" Completion: 06/30/2016","study_completion_date":" 06/30/2016","last_update_posted":"2017-09-15"}]